Süreğen Hazımsızlık, Dispepsi ve Beyin-Bağırsak Etkileşim Bozukluğu
Özet
Süreğen hazımsızlık ve dispepsi; gastroenteroloji ve iç hastalıkları başvurularında sık görülen şikayetlerdendir. Hastalar bu durumu yemek sonrası dolgunluk, erken doyma, epigastrik ağrı veya yanma şeklinde tanımlayabilir. Roma V sınıflaması bu yakınmaları fonksiyonel dispepsi alt tipleri olan postprandiyal distres sendromu (PDS) ve epigastrik ağrı sendromu (EPS) olarak iki başlığa ayırmaktadır. Klinik değerlendirmede öncelikli hedef alarm bulguların olup olmadığını saptamaktır: istemsiz kilo kaybı, disfaji, gastrointestinal kanama, anemi ve 60 yaş üzerinde yeni başlayan dispepsi organik hastalıklar açısından araştırma gerektirir. Alarm bulgusu olmayan 50–60 yaş altı hastalarda Helicobacter pylori noninvaziv testi, sonucuna göre tedavi ve ampirik proton pompa inhibitörü (PPİ) tedavisi ön plandadır. Bu bölümün amacı, dispepsi yakınması olan hastalarda kanıta dayalı, Roma V ile uyumlu ve hasta merkezli bir değerle
Chronic indigestion and dyspepsia are among the most common complaints encountered in gastroenterology and internal medicine clinics. Patients may describe these symptoms as postprandial fullness, early satiety, epigastric pain, or burning. The Roma V classification divides these complaints into two functional dyspepsia subtypes: Postprandial Distress Syndrome (PDS) and Epigastric Pain Syndrome (EPS). The primary goal of clinical evaluation is to determine whether alarm features are present. Unintentional weight loss, dysphagia, gastrointestinal bleeding, anemia, and newly onset dyspepsia in individuals over 60 years of age require further investigation for possible organic disease. In patients younger than 50–60 years without alarm features, noninvasive testing for Helicobacter pylori, treatment according to test results, and empiric proton pump inhibitor (PPİ) therapy are the main approaches. The aim of this section is to provide an evidence-based, Roma V–compatible, and patient-centered evaluation approach for patients presenting with dyspeptic symptoms.
ndirme sunmaktır.
Referanslar
Drossman DA, Chang L, Tack J, et al. Disorders of gut-bra¬in interaction and the Roma V process. Gastroenterology. 2026;170(6):1083–1098.
Törnblom H, Carbone F, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2026;170(6). DOI: 10.1053/j. gastro.2025.10.021.
Moayyedi P, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112(7):988–1013.
Black CJ, Paine PA, Agrawal A, et al. British Society of Gastro-enterology guidelines on the management of functional dys¬pepsia. Gut. 2022;71(9):1697–1723.
Moshiree B, Drossman D, Shaukat A. AGA clinical practice update on evaluation and management of belching, abdomi¬nal bloating, and distention: expert review. Gastroenterology. 2023;165(3):791–800.e3.
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762.
Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Fun-ctional dyspepsia. Lancet. 2020;396(10263):1689–1702.
National Institute for Health and Care Excellence (NICE). Dyspepsia and gastro-oesophageal reflux disease: investiga¬tion and management. Clinical guideline CG184. London: NICE; 2014 (updated 2019).
Tack J, Talley NJ, Camilleri M, et al. Functional gastroduo¬denal disorders. Gastroenterology. 2006;130(5):1466–1479. Roma III referansı için tarihsel bağlam]
Lacy BE, Pimentel M, Brenner DM, et al. ACG clinical guide¬line: management of irritable bowel syndrome. Am J Gastro¬enterol. 2021;116(1):17–44.
